The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis (Q36686365)

15 August 2017

The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis (English)

1 reference

15 August 2017

1 reference

Yuichi Terawaki

1

1 reference

15 August 2017

Takashi Nomiyama

2

1 reference

15 August 2017

Yuko Akehi

3

1 reference

15 August 2017

Hiromasa Takenoshita

4

1 reference

15 August 2017

Ryoko Nagaishi

5

1 reference

15 August 2017

Yoko Tsutsumi

6

1 reference

15 August 2017

Kunitaka Murase

7

1 reference

15 August 2017

Hisahiro Nagasako

8

1 reference

15 August 2017

Nobuya Hamanoue

9

1 reference

15 August 2017

Kaoru Sugimoto

10

1 reference

15 August 2017

Ayako Takada

11

1 reference

15 August 2017

Kenji Ito

12

1 reference

15 August 2017

Yasuhiro Abe

13

1 reference

15 August 2017

Yoshie Sasatomi

14

1 reference

15 August 2017

Satoru Ogahara

15

1 reference

15 August 2017

Hitoshi Nakashima

16

1 reference

15 August 2017

Takao Saito

17

1 reference

15 August 2017

Toshihiko Yanase

18

1 reference

15 August 2017

28 February 2013

1 reference

Diabetology and Metabolic Syndrome

15 August 2017

1 reference

15 August 2017

5

1 reference

15 August 2017

1

1 reference

15 August 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1186/1758-5996-5-10

15 August 2017

0 references

cites work

Efficacy and tolerability of vildagliptin in type 2 diabetic patients on hemodialysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598214

Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598214

Bone: incretin hormones perceiver or receiver?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598214

Cardiovascular biology of the incretin system

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598214

Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598214

Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598214

Incretin-based therapies in complex patients: practical implications and opportunities for maximizing clinical outcomes: a discussion with Dr. Vivian A. Fonseca

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598214

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598214

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598214

The incretin system and its role in type 2 diabetes mellitus

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598214

Effect of renal impairment on the pharmacokinetics of exenatide

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598214

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598214

Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama study.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598214

DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598214

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598214

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598214

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598214

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study

5 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1758-5996-5-10

Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection

21 January 2018

1 reference

12 December 2020

Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes

1 reference

12 December 2020

Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring

1 reference

12 December 2020

Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study

1 reference

12 December 2020

Determination of Kt/V and protein catabolic rate using pre- and postdialysis blood urea nitrogen concentrations

1 reference

12 December 2020

[Special issue: Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012]

1 reference

12 December 2020

Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury

1 reference

12 December 2020

The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.

1 reference

12 December 2020

Identifiers

DOI

10.1186/1758-5996-5-10

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

1 reference